88. Chronic thromboembolic pulmonary hypertension Clinical trials / Disease details

Clinical trials : 157 / Drugs : 107 - (DrugBank : 22) / Drug target genes : 14 - Drug target pathways : 54

1 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-006787-25-DK (EUCTR)	06/07/2022	22/12/2021	The effects of dapagliflozin in patients with elevated blood pressure in the lungs	Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial	Pulmonary arterial hypertensionChronic thromboembolic pulmonary hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 21.1;Classification code 10065151;Term: Idiopathic pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 24.1;Classification code 10085244;Term: Heritable pulmonary arterial hypertension;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 21.0;Classification code 10068740;Term: CTEPH;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Forxiga (dapagliflozin) Product Name: Forxiga INN or Proposed INN: Dapagliflozin	Rigshospitalet The Heart Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 2	Denmark